Evaluating the performance of the Breast and Ovarian Analysis of Disease Incidence Algorithm model in predicting 10-year breast cancer risks in UK Biobank
Open Access
- 12 December 2024
- journal article
- research article
- Published by Oxford University Press (OUP) in JNCI: Journal of the National Cancer Institute
- Vol. 117 (5) , 948-958
Abstract
Background: The Breast and Ovarian Analysis of Disease Incidence Algorithm (BOADICEA) model predicts breast cancer risk using cancer family history, epidemiological, and genetic data. We evaluated its validity in a large prospective cohort. Methods: We assessed model calibration, discrimination and risk classification ability in 217 885 women (6838 incident breast cancers) aged 40-70 years of self-reported White ethnicity with no previous cancer from the UK Biobank. Age-specific risk classification was assessed using relative risk thresholds equivalent to the absolute lifetime risk categories of less than 17%, 17%-30%, and 30% or more, recommended by the National Institute for Health and Care Excellence guidelines. We predicted 10-year risks using BOADICEA v.6 considering cancer family history, questionnaire-based risk factors, a 313–single nucleotide polymorphisms polygenic score, and pathogenic variants. Mammographic density data were not available. Results: The polygenic risk score was the most discriminative risk factor (area under the curve [AUC] = 0.65). Discrimination was highest when considering all risk factors (AUC = 0.66). The model was well calibrated overall (expected-to-observed ratio = 0.99, 95% confidence interval [CI] = 0.97 to 1.02; calibration slope = 0.99, 95% CI = 0.99 to 1.00), and in deciles of predicted risks. Discrimination was similar in women aged younger and older than 50 years. There was some underprediction in women aged younger than 50 years (expected-to-observed ratio = 0.89, 95% CI = 0.84 to 0.94; calibration slope = 0.96, 95% CI = 0.94 to 0.97), which was explained by the higher breast cancer incidence in UK Biobank than the UK population incidence in this age group. The model classified 87.2%, 11.4%, and 1.4% of women in relative risk categories less than 1.6, 1.6-3.1, and at least 3.1, identifying 25.6% of incident breast cancer patients in category relative risk of at least 1.6. Conclusion: BOADICEA, implemented in CanRisk (www.canrisk.org), provides valid 10-year breast cancer risk, which can facilitate risk-stratified screening and personalized breast cancer risk management.Keywords
Funding Information
- Medical Research Council (MR/N013433/1)
- Cancer Research UK (PPRPGM-Nov20\100002)
- National Institute for Health and Care Research
- Cambridge Biomedical Research Centre (NIHR203312)
- Gray Foundation
- European Union’s Horizon 2020 (633784, 634935)
- Genome Canada (#13529)
- Canadian Institutes of Health Research (#155865)
- Ministère de l’Économie et de l’Innovation du Québec through Genome Québec
- Quebec Breast Cancer Foundation
- CHU de Quebec
- British Heart Foundation (RG/18/13/33946, RG/F/23/110103)
- British Heart Foundation Chair (CH/12/2/29428)
- Health Data Research UK
- UK Medical Research Council
- Engineering and Physical Sciences Research Council
- Economic and Social Research Council
- Department of Health and Social Care
- Chief Scientist Office of the Scottish Government Health and Social Care Directorates
- Health and Social Care Research and Development Division
- Public Health Agency
- British Heart Foundation
- Wellcome Trust
This publication has 35 references indexed in Scilit:
- Differences in cancer incidence by broad ethnic group in England, 2013–2017British Journal of Cancer, 2022
- Validation of the BOADICEA model and a 313-variant polygenic risk score for breast cancer risk prediction in a Dutch prospective cohortGenetics in Medicine, 2020
- Analysis of polygenic risk score usage and performance in diverse human populationsNature Communications, 2019
- 10-year performance of four models of breast cancer risk: a validation studyThe Lancet Oncology, 2019
- Polygenic Risk Scores for Prediction of Breast Cancer and Breast Cancer SubtypesThe American Journal of Human Genetics, 2019
- Cost-effectiveness and Benefit-to-Harm Ratio of Risk-Stratified Screening for Breast CancerJAMA Oncology, 2018
- Family history and risk of breast cancer: an analysis accounting for family structureBreast Cancer Research and Treatment, 2017
- Haplotype estimation for biobank-scale data setsNature Genetics, 2016
- On the C‐statistics for evaluating overall adequacy of risk prediction procedures with censored survival dataStatistics in Medicine, 2011
- Epidemiology of breast cancerThe Lancet Oncology, 2001